ERASCA INC. news, videos and press releases - Page 2
For more news please use our advanced search feature.
ERASCA INC. - More news...
ERASCA INC. - More news...
- Erasca Reports Second Quarter 2023 Financial Results and Business Updates
- Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma
- Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline
- Erasca to Present at Upcoming Investor Conferences
- Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor
- Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting
- Erasca Further Strengthens Business Leadership with Two Key Promotions
- Erasca Reports First Quarter 2023 Financial Results and Business Updates
- Erasca to Present at the Bank of America Securities 2023 Health Care Conference
- Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma
- Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting
- Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma
- Erasca Presents Promising Initial Phase 1b Dose Escalation Data from FLAGSHP-1 for ERAS-601 Plus Cetuximab in Patients with Advanced Solid Tumors at the 2023 AACR Annual Meeting
- Erasca Strengthens Clinical and Regulatory Leadership with Two Key Appointments as Company Transitions to Late-Stage Development
- Erasca Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Business Updates
- Erasca Announces Poster Presentation at the 2023 AACR Annual Meeting
- Erasca to Present at the Guggenheim Oncology Conference 2023
- Erasca to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Erasca Announces First Patient Dosed in HERKULES-1 Phase 1b Trial Evaluating ERAS-007 and ERAS-601 MAPKlamp Combination in RAS/MAPK Pathway-Altered Solid Tumors
- Erasca Announces FDA Clearance of IND Application for CNS-Penetrant KRAS G12C Inhibitor ERAS-3490 in KRAS G12C-Mutated Advanced or Metastatic Solid Tumors
- Erasca Announces Exclusive Worldwide License for Pan-RAF Inhibitor Naporafenib
- Erasca Announces Pricing of Underwritten Offering of Common Stock
- Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination
- Erasca to Present at Upcoming Investor Conferences
- Erasca Reports Third Quarter 2022 Financial Results and Business Updates
- Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination
- Erasca Announces Four Poster Presentations at the Upcoming 34th EORTC-NCI-AACR Symposium
- Erasca to Present at the Bank of America Securities Precision Oncology Conference 2022
- Erasca to Present at the Morgan Stanley Global Healthcare Conference
- Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials
